{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:16:45Z","timestamp":1787163405510,"version":"build-2736575974"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI068634"],"award-info":[{"award-number":["UM1 AI068634"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI068636"],"award-info":[{"award-number":["UM1 AI068636"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI106701"],"award-info":[{"award-number":["UM1 AI106701"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Statistical and Data Management Center"},{"DOI":"10.13039\/100006392","name":"AIDS Clinical Trials Group","doi-asserted-by":"publisher","award":["UM1 AI068634"],"award-info":[{"award-number":["UM1 AI068634"]}],"id":[{"id":"10.13039\/100006392","id-type":"DOI","asserted-by":"publisher"}]},{"name":"REACH Delaney","award":["UM1 AI164565"],"award-info":[{"award-number":["UM1 AI164565"]}]},{"name":"REACH Delaney","award":["5U01AI169385"],"award-info":[{"award-number":["5U01AI169385"]}]},{"name":"REACH Delaney","award":["ERC CFAR P30AI124414"],"award-info":[{"award-number":["ERC CFAR P30AI124414"]}]},{"DOI":"10.13039\/501100003554","name":"Lundbeck Foundation","doi-asserted-by":"publisher","award":["R313-2019-790"],"award-info":[{"award-number":["R313-2019-790"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeck Foundation","doi-asserted-by":"publisher","award":["R381-2021-1405"],"award-info":[{"award-number":["R381-2021-1405"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BEAT-HIV Delaney","award":["UM1AI164570"],"award-info":[{"award-number":["UM1AI164570"]}]},{"name":"BEAT-HIV Delaney","award":["R01AI162646"],"award-info":[{"award-number":["R01AI162646"]}]},{"name":"BEAT-HIV Delaney","award":["U01AI169767"],"award-info":[{"award-number":["U01AI169767"]}]},{"name":"BEAT-HIV Delaney","award":["P01AI131338"],"award-info":[{"award-number":["P01AI131338"]}]},{"name":"Penn CFAR","award":["P30AI045008"],"award-info":[{"award-number":["P30AI045008"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Development of a screening assay for the clinical use of broadly neutralizing antibodies (bnAbs) is a priority for HIV therapy and cure initiatives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We assessed the PhenoSense Monoclonal Antibody Assay (Labcorp-Monogram Biosciences), which is Clinical Laboratory Improvement Amendments (CLIA) validated and has been used prospectively and retrospectively in multiple recent bnAb clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>When performed on plasma and longitudinal peripheral blood mononuclear cell samples (before and during antiretroviral therapy, respectively), as sourced from a recent clinical trial, the PhenoSense assay produced robust reproducibility, concordance across sample types, and expected ranges in the susceptibility measures of bnAbs in clinical development. When applied retrospectively to baseline samples from 3 recent studies, the PhenoSense assay correlated with published laboratory-based study evaluations, but baseline bnAb susceptibility was not consistently predictive of durable virus suppression. Assessment of assay feasibility in 4 recent clinical studies provides estimates of assay success rate and processing time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The PhenoSense Monoclonal Antibody Assay provides reproducible bnAb susceptibility measurements across relevant sample types yet is not consistently predictive of virus suppression. Logistical and operational assay requirements can affect timely clinical trial conduct. These results inform bnAb studies in development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiae486","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T23:23:32Z","timestamp":1729553012000},"page":"424-434","source":"Crossref","is-referenced-by-count":8,"title":["Evaluation and Real-world Experience of a Neutralization Susceptibility Screening Assay for Broadly Neutralizing Anti\u2013HIV-1 Antibodies"],"prefix":"10.1093","volume":"231","author":[{"given":"Marie H\u00f8st","family":"Pahus","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Aarhus University Hospital ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zheng","sequence":"additional","affiliation":[{"name":"Chan School of Public Health, Harvard University , Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxine","family":"Olefsky","sequence":"additional","affiliation":[{"name":"Chan School of Public Health, Harvard University , Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper Damsgaard","family":"Gunst","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Aarhus University Hospital ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5345-7942","authenticated-orcid":false,"given":"Pablo","family":"Tebas","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, Department of Medicine, University of Pennsylvania , Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babafemi","family":"Taiwo","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, Department of Medicine, Northwestern University , Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole S","family":"S\u00f8gaard","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Aarhus University Hospital ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Peluso","sequence":"additional","affiliation":[{"name":"Division of HIV, Infectious Diseases and Global Medicine, Department of Medicine, University of California San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Lie","sequence":"additional","affiliation":[{"name":"Labcorp-Monogram Biosciences , South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline D","family":"Reeves","sequence":"additional","affiliation":[{"name":"Labcorp-Monogram Biosciences , South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos J","family":"Petropoulos","sequence":"additional","affiliation":[{"name":"Labcorp-Monogram Biosciences , South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Caskey","sequence":"additional","affiliation":[{"name":"Department of Clinical Investigation, Rockefeller University , New York City, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9773-0071","authenticated-orcid":false,"given":"Katharine J","family":"Bar","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, Department of Medicine, University of Pennsylvania , Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"2025022016345270000_jiae486-B1","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1038\/s41591-023-02547-6","article-title":"Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial","volume":"29","author":"Gunst","year":"2023","journal-title":"Nat Med"},{"key":"2025022016345270000_jiae486-B2","doi-asserted-by":"crossref","first-page":"6473","DOI":"10.1038\/s41467-022-34171-2","article-title":"Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8(+) T cell immunity","volume":"13","author":"Ros\u00e1s-Umbert","year":"2022","journal-title":"Nat Commun"},{"key":"2025022016345270000_jiae486-B3","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1038\/s41591-022-02023-7","article-title":"Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b\/2a, randomized trial","volume":"28","author":"Gunst","year":"2022","journal-title":"Nat Med"},{"key":"2025022016345270000_jiae486-B4","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination therapy with anti-HIV-1 antibodies maintains viral suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"2025022016345270000_jiae486-B5","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1084\/jem.20180936","article-title":"Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117","volume":"215","author":"Cohen","year":"2018","journal-title":"J Exp Med"},{"key":"2025022016345270000_jiae486-B6","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","article-title":"Effect of HIV antibody VRC01 on viral rebound after treatment interruption","volume":"375","author":"Bar","year":"2016","journal-title":"N Engl J Med"},{"key":"2025022016345270000_jiae486-B7","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M14-1084","article-title":"Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial","volume":"161","author":"Lennox","year":"2014","journal-title":"Ann Intern Med"},{"key":"2025022016345270000_jiae486-B8","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1128\/AAC.44.4.920-928.2000","article-title":"A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1","volume":"44","author":"Petropoulos","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2025022016345270000_jiae486-B9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/jama.283.2.229","article-title":"Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens","volume":"283","author":"Havlir","year":"2000","journal-title":"JAMA"},{"key":"2025022016345270000_jiae486-B10","doi-asserted-by":"crossref","first-page":"10948","DOI":"10.1073\/pnas.97.20.10948","article-title":"Antiretroviral resistance during successful therapy of HIV type 1 infection","volume":"97","author":"Martinez-Picado","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025022016345270000_jiae486-B11","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/jac\/dkp293","article-title":"Correlation between the Trofile test and virological response to a short-term maraviroc exposure in HIV-infected patients","volume":"64","author":"Genebat","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2025022016345270000_jiae486-B12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","article-title":"Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1","volume":"409","author":"Sarzotti-Kelsoe","year":"2014","journal-title":"J Immunol Methods"},{"key":"2025022016345270000_jiae486-B13","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev-med-061016-041032","article-title":"New-generation high-potency and designer antibodies: role in HIV-1 treatment","volume":"69","author":"Gama","year":"2018","journal-title":"Annu Rev Med"},{"key":"2025022016345270000_jiae486-B14","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1128\/JVI.01791-15","article-title":"New member of the V1V2-directed CAP256-VRC26 lineage that shows increased breadth and exceptional potency","volume":"90","author":"Doria-Rose","year":"2016","journal-title":"J Virol"},{"key":"2025022016345270000_jiae486-B15","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1128\/JVI.02658-10","article-title":"Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop","volume":"85","author":"Moore","year":"2011","journal-title":"J Virol"},{"key":"2025022016345270000_jiae486-B16","article-title":"Rebound dynamics following immunotherapy with an HIV vaccine, TLR9 agonist, and bNAbs","author":"Peluso"},{"key":"2025022016345270000_jiae486-B17","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41586-022-04797-9","article-title":"Combination anti-HIV antibodies provide sustained virological suppression","volume":"606","author":"Sneller","year":"2022","journal-title":"Nature"},{"key":"2025022016345270000_jiae486-B18","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41586-022-04597-1","article-title":"Prolonged viral suppression with anti-HIV-1 antibody therapy","volume":"606","author":"Gaebler","year":"2022","journal-title":"Nature"},{"key":"2025022016345270000_jiae486-B19","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","article-title":"Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition","volume":"384","author":"Corey","year":"2021","journal-title":"N Engl J Med"},{"key":"2025022016345270000_jiae486-B20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/COH.0000000000000798","article-title":"Development of screening assays for use of broadly neutralizing antibodies in people with HIV","volume":"18","author":"Lynch","year":"2023","journal-title":"Curr Opin HIV AIDS"},{"key":"2025022016345270000_jiae486-B21","doi-asserted-by":"crossref","first-page":"e1005520","DOI":"10.1371\/journal.ppat.1005520","article-title":"Optimal combinations of broadly neutralizing antibodies for prevention and treatment of HIV-1 clade C infection","volume":"12","author":"Wagh","year":"2016","journal-title":"PLoS Pathog"},{"key":"2025022016345270000_jiae486-B22","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1097\/QAD.0000000000003575","article-title":"Susceptibility to 3BNC117 and 10-1074 in ART suppressed chronically infected persons","volume":"37","author":"Tebas","year":"2023","journal-title":"AIDS"},{"key":"2025022016345270000_jiae486-B23","article-title":"BEAT2 primary trial outcomes: PEGIFN-a2b, 3BNC117 and 10-1074 in chronic HIV infection","author":"Tebas"},{"key":"2025022016345270000_jiae486-B24","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1146\/annurev-pathol-050520-112001","article-title":"In vivo dynamics of the latent reservoir for HIV-1: new insights and implications for cure","volume":"17","author":"Siliciano","year":"2022","journal-title":"Annu Rev Pathol"},{"key":"2025022016345270000_jiae486-B25","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/s41591-020-1022-1","article-title":"Recommendations for measuring HIV reservoir size in cure-directed clinical trials","volume":"26","author":"Abdel-Mohsen","year":"2020","journal-title":"Nat Med"},{"key":"2025022016345270000_jiae486-B26","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.3389\/fmicb.2019.02878","article-title":"New frontiers in measuring and characterizing the HIV reservoir","volume":"10","author":"Falcinelli","year":"2019","journal-title":"Front Microbiol"},{"key":"2025022016345270000_jiae486-B27","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/nm.4411","article-title":"Defining total-body AIDS-virus burden with implications for curative strategies","volume":"23","author":"Estes","year":"2017","journal-title":"Nat Med"},{"key":"2025022016345270000_jiae486-B28","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1172\/JCI120194","article-title":"HIV-1 latent reservoir size and diversity are stable following brief treatment interruption","volume":"128","author":"Salantes","year":"2018","journal-title":"J Clin Invest"},{"key":"2025022016345270000_jiae486-B29","doi-asserted-by":"crossref","first-page":"E11341","DOI":"10.1073\/pnas.1813512115","article-title":"Relationship between intact HIV-1 proviruses in circulating CD4(+) T cells and rebound viruses emerging during treatment interruption","volume":"115","author":"Lu","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025022016345270000_jiae486-B30","doi-asserted-by":"crossref","first-page":"e00170-21","DOI":"10.1128\/mBio.00170-21","article-title":"Viral rebound kinetics correlate with distinct HIV antibody features","volume":"12","author":"Bartsch","year":"2021","journal-title":"mBio"},{"key":"2025022016345270000_jiae486-B31","doi-asserted-by":"crossref","first-page":"108502","DOI":"10.1016\/j.celrep.2020.108502","article-title":"HIV antibody Fc N-linked glycosylation is associated with viral rebound","volume":"33","author":"Offersen","year":"2020","journal-title":"Cell Rep"},{"key":"2025022016345270000_jiae486-B32","doi-asserted-by":"crossref","first-page":"e03444-20","DOI":"10.1128\/mBio.03444-20","article-title":"Phospholipid metabolism is associated with time to HIV rebound upon treatment interruption","volume":"12","author":"Giron","year":"2021","journal-title":"mBio"},{"key":"2025022016345270000_jiae486-B33","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/QAD.0000000000002476","article-title":"Plasma and antibody glycomic biomarkers of time to HIV rebound and viral setpoint","volume":"34","author":"Giron","year":"2020","journal-title":"AIDS"},{"key":"2025022016345270000_jiae486-B34","doi-asserted-by":"crossref","first-page":"101122","DOI":"10.1016\/j.xcrm.2023.101122","article-title":"Peripheral blood biomarkers predict viral rebound following antiretroviral therapy discontinuation in SIV-infected, early ART-treated rhesus macaques","volume":"4","author":"Aid","year":"2023","journal-title":"Cell Rep Med"},{"key":"2025022016345270000_jiae486-B35","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/cid\/ciab541","article-title":"Time to viral rebound after interruption of modern antiretroviral therapies","volume":"74","author":"Li","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025022016345270000_jiae486-B36","first-page":"343","article-title":"The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption","volume":"30","author":"Li","year":"2016","journal-title":"AIDS"},{"key":"2025022016345270000_jiae486-B37","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1128\/JVI.02139-15","article-title":"Origin of rebound plasma HIV includes cells with identical proviruses that are transcriptionally active before stopping of antiretroviral therapy","volume":"90","author":"Kearney","year":"2016","journal-title":"J Virol"},{"key":"2025022016345270000_jiae486-B38","doi-asserted-by":"crossref","first-page":"e1008241","DOI":"10.1371\/journal.pcbi.1008241","article-title":"Models of SIV rebound after treatment interruption that involve multiple reactivation events","volume":"16","author":"van Dorp","year":"2020","journal-title":"PLoS Comput Biol"},{"key":"2025022016345270000_jiae486-B39","doi-asserted-by":"crossref","first-page":"e1005535","DOI":"10.1371\/journal.ppat.1005535","article-title":"Real-time predictions of reservoir size and rebound time during antiretroviral therapy interruption trials for HIV","volume":"12","author":"Hill","year":"2016","journal-title":"PLoS Pathog"},{"key":"2025022016345270000_jiae486-B40","doi-asserted-by":"crossref","first-page":"e1006359","DOI":"10.1371\/journal.ppat.1006359","article-title":"Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy","volume":"13","author":"Fennessey","year":"2017","journal-title":"PLoS Pathog"},{"key":"2025022016345270000_jiae486-B41","doi-asserted-by":"crossref","first-page":"e1005740","DOI":"10.1371\/journal.ppat.1005740","article-title":"Modeling of experimental data supports HIV reactivation from latency after treatment interruption on average once every 5\u20138 days","volume":"12","author":"Pinkevych","year":"2016","journal-title":"PLoS Pathog"},{"key":"2025022016345270000_jiae486-B42","doi-asserted-by":"crossref","first-page":"e1005000","DOI":"10.1371\/journal.ppat.1005000","article-title":"HIV reactivation from latency after treatment interruption occurs on average every 5\u20138 days\u2014implications for HIV remission","volume":"11","author":"Pinkevych","year":"2015","journal-title":"PLoS Pathog"},{"key":"2025022016345270000_jiae486-B43","doi-asserted-by":"crossref","first-page":"e1002493","DOI":"10.1371\/journal.pmed.1002493","article-title":"Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a phase 1 open-label clinical trial in healthy adults","volume":"15","author":"Gaudinski","year":"2018","journal-title":"PLoS Med"},{"key":"2025022016345270000_jiae486-B44","doi-asserted-by":"crossref","first-page":"e1002435","DOI":"10.1371\/journal.pmed.1002435","article-title":"Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: results of a phase 1 randomized trial","volume":"14","author":"Mayer","year":"2017","journal-title":"PLoS Med"},{"key":"2025022016345270000_jiae486-B45","doi-asserted-by":"crossref","first-page":"e1004966","DOI":"10.1371\/journal.ppat.1004966","article-title":"Capacity of broadly neutralizing antibodies to inhibit HIV-1 cell-cell transmission is strain- and epitope-dependent","volume":"11","author":"Reh","year":"2015","journal-title":"PLoS Pathog"},{"key":"2025022016345270000_jiae486-B46","doi-asserted-by":"crossref","first-page":"e1002634","DOI":"10.1371\/journal.ppat.1002634","article-title":"Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies","volume":"8","author":"Abela","year":"2012","journal-title":"PLoS Pathog"},{"key":"2025022016345270000_jiae486-B47","doi-asserted-by":"crossref","first-page":"eabd8179","DOI":"10.1126\/scitranslmed.abd8179","article-title":"Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption","volume":"13","author":"Gondim","year":"2021","journal-title":"Sci Transl Med"},{"key":"2025022016345270000_jiae486-B48","doi-asserted-by":"crossref","first-page":"32066","DOI":"10.1073\/pnas.2020617117","article-title":"Autologous IgG antibodies block outgrowth of a substantial but variable fraction of viruses in the latent reservoir for HIV-1","volume":"117","author":"Bertagnolli","year":"2020","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiae486\/60094286\/jiae486.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/2\/424\/60094286\/jiae486.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/231\/2\/424\/60094286\/jiae486.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T11:36:21Z","timestamp":1740051381000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/231\/2\/424\/7832602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":48,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,10,23]]},"published-print":{"date-parts":[[2025,2,20]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiae486","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2,15]]},"published":{"date-parts":[[2024,10,23]]}}}